Farshid Gelareh, Rush Gill
BreastScreen South Australia, Wayville, Australia.
Cancer. 2003 Dec 25;99(6):357-64. doi: 10.1002/cncr.11785.
Fine-needle aspiration biopsy (FNAB) is used as the first-line diagnostic test for lesions that require morphologic assessment in the authors' breast cancer screening program. A positive cytologic diagnosis is an indication to proceed to definitive surgery. Core biopsy is used if FNAB is not diagnostic. In the context of increased use of core biopsy at other centers, the authors reviewed their experience with the cytologic assessment of highly suspicious microcalcifications.
Between January 1996 and June 2000, the dominant radiologic abnormality was classified prospectively as high-grade microcalcifications in 182 lesions. Data were recorded on patient demographics, radiologic features, and the findings of FNAB and core biopsy, if performed. The results of the screening assessment were then compared with the final histologic findings.
Overall, 15.6% of all radiologically high-grade lesions were microcalcifications. The mean patient age was 58.76 years. The lesions had a mean size of 38.49 mm (range, 5-200 mm), and 92.31% of high-grade microcalcifications proved to be malignant. Among the cases evaluated by FNAB, a positive cytologic diagnosis of malignancy was made in 70.93% of lesions, without any false-positive diagnoses and obviating the need for diagnostic core biopsy. FNAB had a sensitivity of 77.22% and a positive predictive value (PPV) of 100%. When core biopsy was performed due to the absence of a positive cytologic diagnosis, it averted the need for open biopsy in 76% of lesions.
Where there is access to skilled cytopathologists, FNAB can provide a highly accurate, rapid, and cost-effective means of triage of patients who would benefit most from the more expensive core biopsy.
在作者的乳腺癌筛查项目中,细针穿刺活检(FNAB)被用作对需要进行形态学评估的病变的一线诊断测试。细胞学诊断阳性是进行确定性手术的指征。如果FNAB不能确诊,则使用粗针活检。在其他中心粗针活检使用增加的背景下,作者回顾了他们对高度可疑微钙化进行细胞学评估的经验。
1996年1月至2000年6月期间,前瞻性地将182个病变中主要的放射学异常分类为高级别微钙化。记录患者人口统计学数据、放射学特征以及FNAB和粗针活检(如果进行了)的结果。然后将筛查评估结果与最终组织学结果进行比较。
总体而言,所有放射学高级别病变中有15.6%为微钙化。患者平均年龄为58.76岁。病变平均大小为38.49毫米(范围为5 - 200毫米),92.31%的高级别微钙化被证明为恶性。在通过FNAB评估的病例中,70.93%的病变细胞学诊断为恶性阳性,无任何假阳性诊断,无需进行诊断性粗针活检。FNAB的敏感性为77.22%,阳性预测值(PPV)为100%。当由于细胞学诊断阴性而进行粗针活检时,76%的病变避免了开放活检的需要。
在有熟练细胞病理学家的情况下,FNAB可以为那些从更昂贵的粗针活检中获益最大的患者提供一种高度准确、快速且具有成本效益的分流方法。